For today’s episode, I interviewed Anu Osinusi, Vice President of Clinical Research for Hepatitis, Respiratory and Emerging Viruses at Gilead. She talks about how Gilead is at the forefront of battling viral diseases as well as the solutions they are formulating to ensure that each and every person has access to treatments for future pandemics and to preserve global health across the globe.

Who’s The Guest? Anu Osinusi serves as the Vice President of Clinical Development at Gilead Sciences. As a clinician-researcher with more than 15 years of experience in drug development, liver diseases, infectious diseases, and global health, she is responsible for overseeing the Viral Hepatitis (Hep B, C, and D), Respiratory and Emerging (COVID-19, Ebola, RSV, and others) Viruses portfolio.

Episode Sponsored By Gilead

Episode Resources

• Connect with Arundhati Parmar
• aparmar@medcitynews.com
• https://twitter.com/aparmarbb?lang=en
• https://medcitynews.com/
• Connect with Anu Osinusi
• https://www.gilead.com/ 
• https://www.linkedin.com/in/anu-osinusi-aoo

Review, Subscribe and Share If you like what you hear please leave a review by clicking here

Make sure you’re subscribed to the podcast so you get the latest episodes.

• Click here to subscribe with Apple Podcasts
• Click here to subscribe with Spotify
• Click here to subscribe with Podbean
• Click here to subscribe with RSS